

Set Name Query

side by side

Hit Count Set Name

result set

DB=USPT,PGPB; PLUR=YES; OP=ADJ

<u>L4</u>	(gp39 or cd40L or cd40 adj ligand or 5c8) same (antibod\$) and ('89-76' or '24-31')	23	<u>L4</u>
<u>L3</u>	(gp39 or cd40L or cd40 adj ligand or 5c8) same (antibod\$)same (diabetes)	29	<u>L3</u>
<u>L2</u>	(gp39 or cd40L or cd40 adj ligand or 5c8) same (antibod\$) and diabetes	305	<u>L2</u>
<u>L1</u>	noelle-randolph\$	18	<u>L1</u>

END OF SEARCH HISTORY

[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 10 of 23 returned.**

-
- ☐ 1. [20030103971](#). 12 Sep 02. 05 Jun 03. Immunoregulatory antibodies and uses thereof. Hariharan, Kandasamy, et al. 424/141.1; 424/155.1 A61K039/395.
-
- ☐ 2. [20030072754](#). 11 Oct 02. 17 Apr 03. CD154 blockade therapy for pancreatic islet tissue transplantation. Kenyon, Norma S., et al. 424/144.1; A61K039/395.
-
- ☐ 3. [20030031668](#). 27 Sep 02. 13 Feb 03. Treatment of immune complex disease with anti-CD40L antibodies. Kalled, Susan L., et al. 424/144.1; A61K039/395.
-
- ☐ 4. [20030027744](#). 18 Apr 02. 06 Feb 03. Use of a CD40:CD154 binding interruptor to treat immunological complications of the eye. Dana, M. Reza, et al. 514/1; 514/2 A61K031/00 A61K038/00.
-
- ☐ 5. [20030012781](#). 06 Jun 01. 16 Jan 03. Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof. Darrell, Anderson, et al. 424/131.1; 424/93.21 A61K048/00 A61K039/395.
-
- ☐ 6. [20020119151](#). 19 Apr 02. 29 Aug 02. CD154 blockade therapy for therapeutic protein inhibitor syndrome. Adelman, Burt. 424/144.1; A61K039/395.
-
- ☐ 7. [20020119150](#). 09 Apr 02. 29 Aug 02. Use of a CD40:CD154 binding interruptor to prevent counter-adaptive immune responses, particularly graft rejection. Kirk, Allan D., et al. 424/144.1; A61K039/395.
-
- ☐ 8. [20020071840](#). 12 Dec 01. 13 Jun 02. Method of therapeutic administration of anti-CD40L compounds. Kalled, Susan L., et al. 424/131.1; 424/144.1 A61K039/395.
-
- ☐ 9. [20020048579](#). 16 Apr 01. 25 Apr 02. Ex vivo treatment of allogeneic and xenogeneic donor T-cells containing compositions (bone marrow) using gp39 antagonists and use thereof. Noelle, Randolph J., et al. 424/144.1; 424/93.7 435/372 A61K039/395 C12N005/08.
-
- ☐ 10. [20020028178](#). 16 May 01. 07 Mar 02. Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications. Hanna, Nabil, et al. 424/1.49; 424/143.1 A61K039/395 A61K051/00.
-

[Generate Collection](#)[Print](#)

[Generate Collection](#)[Print](#)**Search Results - Record(s) 11 through 20 of 23 returned.**

-
- ☐ 11. [20020022020](#). 14 Sep 01. 21 Feb 02. Ex vivo treatment of allogeneic and xenogeneic donor T-cells containing compositions (bone marrow) using gp39 antagonists and use thereof. Noelle, Randolph J., et al. 424/93.71; 435/372 A61K045/00 C12N005/08.
-
- ☐ 12. [20020009450](#). 08 May 01. 24 Jan 02. Treatment of T cell mediated autoimmune disorders. Noelle, Randolph J., et al. 424/154.1; 424/142.1 A61K039/395.
-
- ☐ 13. [20020009444](#). 25 Apr 01. 24 Jan 02. Intrathecal administration of rituximab for treatment of central nervous system lymphomas. Grillo-Lopez, Antonio J.. 424/142.1; 424/1.49 424/1.65 514/251 514/283 A61K051/10 A61K039/395 A61K051/04 A61K031/525 A61K031/475.
-
- ☐ 14. [20020006404](#). 31 Jan 01. 17 Jan 02. Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications. Hanna, Nabil, et al. 424/142.1; 424/155.1 A61K039/395.
-
- ☐ 15. [20010018041](#). 16 Apr 01. 30 Aug 01. Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy. Hanna, Nabil, et al. 424/1.49; 424/181.1 A61K039/395.
-
- ☐ 16. [6506383](#). 14 Jun 99; 14 Jan 03. Methods of suppressing immune responses to transplanted tissues and organs with gp39-specific antibodies. Black; Amelia, et al. 424/154.1; 424/130.1 424/133.1 424/141.1 424/143.1 424/144.1 424/153.1 424/173.1 530/387.1 530/387.3 530/388.1 530/388.2 530/388.22 530/388.7 530/388.73 530/388.75. A61K039/395 C07K016/28.
-
- ☐ 17. [6440418](#). 08 Sep 97; 27 Aug 02. Methods of treating autoimmune diseases with gp39-specific antibodies. Black; Amelia, et al. 424/154.1; 424/130.1 424/133.1 424/141.1 424/143.1 424/144.1 424/153.1 424/173.1 530/387.1 530/387.3 530/388.1 530/388.2 530/388.22 530/388.7 530/388.73 530/388.75. A61K039/395 C07K016/28.
-
- ☐ 18. [6328964](#). 18 May 98; 11 Dec 01. Method to treat multiple sclerosis with GP39-specific antibodies. Noelle; Randolph J., et al. 424/154.1; 424/130.1 424/133.1 424/141.1 424/142.1 424/143.1 424/144.1 424/153.1 424/173.1 530/387.1 530/387.3 530/388.1 530/388.2 530/388.22 530/388.7 530/388.73 530/388.75. A61K039/395 C07K016/28.
-
- ☐ 19. [6312692](#). 30 Apr 98; 06 Nov 01. Method of treating graft-versus-host disease with anti-GP39 antibodies and bone marrow cells. Noelle; Randolph J., et al. 424/154.1; 424/130.1 424/141.1 424/143.1 424/144.1 424/153.1 424/173.1 424/520 424/577 424/93.7 424/93.71 435/332 435/334 435/343 435/343.1 435/343.2 435/346 530/387.1 530/388.1 530/388.2 530/388.22 530/388.7 530/388.73 530/388.75. A61K039/395 A61K035/28 C07K016/28.
-
- ☐ 20. [6001358](#). 07 Nov 95; 14 Dec 99. Humanized antibodies to human gp39, compositions containing thereof. Black; Amelia, et al. 424/154.1; 424/130.1 424/133.1 424/141.1 424/143.1 424/144.1 424/153.1 424/173.1 530/387.1 530/387.3 530/388.1 530/388.2 530/388.22 530/388.7 530/388.73 530/388.75 536/23.53. A61K039/395 C07K016/28.
-

Generate Collection

Print

Search Results - Record(s) 21 through 23 of 23 returned.

☐ 21. 5876718. 27 Mar 98; 02 Mar 99. Methods of inducing T cell non-responsiveness to transplanted tissues and of treating graft-versus-host-disease with anti-gp39 antibodies. Noelle; Randolph J., et al. 424/154.1; 424/130.1 424/133.1 424/134.1 424/141.1 424/143.1 424/193.1 435/326 435/332 435/334 435/343 435/343.1 530/388.2 530/388.22 530/388.7 530/388.73 530/388.75. A61K039/395 C07K016/28 C12N005/12.

☐ 22. 5833987. 07 Jun 95; 10 Nov 98. Treatment of T cell mediated autoimmune disorders. Noelle; Randolph J., et al. 424/154.1; 424/130.1 424/133.1 424/141.1 424/142.1 424/143.1 424/144.1 424/153.1 424/173.1. A61K039/395.

☐ 23. 5747037. 07 Jun 95; 05 May 98. Anti-GP39 antibodies. Noelle; Randolph J., et al. 424/154.1; 424/130.1 424/141.1 424/143.1 424/144.1 424/153.1 424/173.1 435/326 435/332 435/334 435/343 435/343.1 435/343.2 435/346 435/70.21 530/387.1 530/388.1 530/388.2 530/388.22 530/388.7 530/388.73 530/388.75. A01K039/395 C07K016/28 C12N005/12.

Generate Collection

Print

Term	Documents
GP39	237
GP39S	0
CD40L	877
CD40LS	2
CD40	2267
CD40S	0
LIGAND	58523
LIGANDS	47955
5C8	98
5C8S	0
89-76	21
((GP39 OR CD40L OR CD40 ADJ LIGAND OR 5C8) SAME (ANTIBOD\$) AND ('89-76' OR '24-31')).USPT,PGPB.	23

[There are more results than shown above. Click here to view the entire set.](#)

[Previous Page](#)[Next Page](#)

☐ Generate Collection

L1: Entry 1 of 18

File: PGPB

Dec 12, 2002

PGPUB-DOCUMENT-NUMBER: 20020187135
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020187135 A1

TITLE: METHODS FOR INDUCING ANTIGEN-SPECIFIC T CELL TOLERANCE

PUBLICATION-DATE: December 12, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
NOELLE, RANDOLPH J.	CORNISH	NH	US	
FOY, TERESA M.	LEBANON	NH	US	
DURIE, FIONA H.	LEBANON	NH	US	

APPL-NO: 09/ 164568 [PALM]
DATE FILED: October 1, 1998

CONTINUED PROSECUTION APPLICATION: This is a publication of a continued prosecution application (CPA) filed under 37 CFR 1.53(d).

RELATED-US-APPL-DATA:

Application 09/164568 is a continuation-of US application 08/232929, filed April 25, 1994, US Patent No. 5869049
Application 08/232929 is a continuation-in-part-of US application 08/116255, filed September 2, 1993, ABANDONED

INT-CL: [07] A61 K 38/16, A01 N 63/00, A61 K 39/395, A61 K 39/40, A61 K 39/42, A61 K 39/00, A61 K 39/38, C07 K 1/00, C07 K 14/00, C07 K 17/00, C12 P 21/08, C07 K 16/00, A61 K 35/26, A61 K 35/28, A01 N 25/00

US-CL-PUBLISHED: 424/93.71; 424/133.1, 424/143.1, 424/173.1, 424/134.1, 424/153.1, 424/141.1, 424/154.1, 424/184.1, 424/192.1, 424/577, 424/578, 514/8, 514/885, 530/350, 530/387.3, 530/388.1, 530/388.2, 530/388.22, 530/388.7, 530/388.73, 530/388.75
US-CL-CURRENT: 424/93.71; 424/133.1, 424/134.1, 424/141.1, 424/143.1, 424/153.1, 424/154.1, 424/173.1, 424/184.1, 424/192.1, 424/577, 424/578, 514/8, 514/885, 530/350, 530/387.3, 530/388.1, 530/388.2, 530/388.22, 530/388.7, 530/388.73, 530/388.75

REPRESENTATIVE-FIGURES: NONE

ABSTRACT:

Methods for inducing antigen-specific T cell tolerance are disclosed. The methods involve contacting a T cell with: 1) a cell which presents antigen to the T cell, wherein a ligand on the cell interacts with a receptor on the surface of the T cell which mediates contact-dependent helper effector function; and 2) an antagonist of the receptor on the surface of the T cell which inhibits interaction of the ligand on the antigen presenting cell with the receptor on the T cell. In a preferred embodiment, the cell which presents antigen to the T cell is a B cell and the receptor on the surface of the T cell which mediates contact-dependent helper effector function is gp39. Preferably, the antagonist is an anti-gp39 antibody or a soluble gp39 ligand (e.g., soluble CD40). The methods of the invention can be used to induce T cell tolerance to a soluble antigen or to an allogeneic cell. The methods of the invention can also be used to induce tolerance in cases of bone marrow transplantation and other organ transplants and to inhibit graft-versus-host disease.

RELATED APPLICATIONS

[0001] This application is a Continuation-in-Part of U.S. patent application Ser. No. 08/116,255, filed Sep. 2, 1993, the contents of which are incorporated herein by reference.

[Generate Collection](#)[Print](#)**Search Results - Record(s) 11 through 18 of 18 returned.**

-
- ☐ 11. [6312692](#). 30 Apr 98; 06 Nov 01. Method of treating graft-versus-host disease with anti-GP39 antibodies and bone marrow cells. [Noelle; Randolph J.](#), et al. 424/154.1; 424/130.1 424/141.1 424/143.1 424/144.1 424/153.1 424/173.1 424/520 424/577 424/93.7 424/93.71 435/332 435/334 435/343 435/343.1 435/343.2 435/346 530/387.1 530/388.1 530/388.2 530/388.22 530/388.7 530/388.73 530/388.75. A61K039/395 A61K035/28 C07K016/28.
-
- ☐ 12. [5942229](#). 07 Jun 95; 24 Aug 99. Method for prolonged suppression of humoral immune response to a thymus-dependent antigen therapeutic agent. [Noelle; Randolph J.](#), et al. 424/154.1; 424/130.1 424/133.1 424/134.1 424/141.1 424/143.1 424/144.1 424/153.1 424/173.1 424/185.1 424/195.11 514/2 514/8 514/885 530/350 530/387.1 530/387.3 530/388.1 530/388.2 530/388.22 530/388.7 530/388.73 530/388.75. A61K039/395 A61K038/17 A61K035/12.
-
- ☐ 13. [5902585](#). 05 Aug 97; 11 May 99. Methods of inducing T cell unresponsiveness to donor tissue or organ in a recipient with GP39 antagonists. [Noelle; Randolph J.](#), et al. 424/144.1; 424/130.1 424/133.1 424/134.1 424/141.1 424/143.1 424/154.1 424/173.1 514/2 514/8 514/885 530/350 530/387.1 530/387.3 530/388.1 530/388.2 530/388.22 530/388.7 530/388.73 530/388.75. A61K039/395 A61K035/26 C07K016/28 C07K014/435.
-
- ☐ 14. [5876718](#). 27 Mar 98; 02 Mar 99. Methods of inducing T cell non-responsiveness to transplanted tissues and of treating graft-versus-host-disease with anti-gp39 antibodies. [Noelle; Randolph J.](#), et al. 424/154.1; 424/130.1 424/133.1 424/134.1 424/141.1 424/143.1 424/193.1 435/326 435/332 435/334 435/343 435/343.1 530/388.2 530/388.22 530/388.7 530/388.73 530/388.75. A61K039/395 C07K016/28 C12N005/12.
-
- ☐ 15. [5869049](#). 25 Apr 94; 09 Feb 99. Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists. [Noelle; Randolph J.](#), et al. 424/154.1; 424/130.1 424/134.1 424/143.1 424/144.1 424/173.1 424/233.1 514/12 514/2 514/8. A61K039/395 A61K037/02 A61K037/04.
-
- ☐ 16. [5833987](#). 07 Jun 95; 10 Nov 98. Treatment of T cell mediated autoimmune disorders. [Noelle; Randolph J.](#), et al. 424/154.1; 424/130.1 424/133.1 424/141.1 424/142.1 424/143.1 424/144.1 424/153.1 424/173.1. A61K039/395.
-
- ☐ 17. [5747037](#). 07 Jun 95; 05 May 98. Anti-GP39 antibodies. [Noelle; Randolph J.](#), et al. 424/154.1; 424/130.1 424/141.1 424/143.1 424/144.1 424/153.1 424/173.1 435/326 435/332 435/334 435/343 435/343.1 435/343.2 435/346 435/70.21 530/387.1 530/388.1 530/388.2 530/388.22 530/388.7 530/388.73 530/388.75. A01K039/395 C07K016/28 C12N005/12.
-
- ☐ 18. [5683693](#). 25 Apr 94; 04 Nov 97. Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40. [Noelle; Randolph J.](#), et al. 424/144.1; 424/130.1 424/133.1 424/134.1 424/141.1 424/143.1 424/154.1 424/173.1 514/2 514/8 514/885. A61K039/395 A61K038/17.
-

[Generate Collection](#)[Print](#)

Term	Documents
NOELLE-RANDOLPH\$	0
NOELLE-RANDOLPH	2
NOELLE-RANDOLPH-J	16
NOELLE-RANDOLPH\$.USPT,PGPB.	18
(NOELLE-RANDOLPH\$).USPT,PGPB.	18

[Previous Page](#)[Next Page](#)

☐ Generate Collection

L3: Entry 16 of 29

File: USPT

Jun 25, 2002

DOCUMENT-IDENTIFIER: US 6410711 B1

**** See image for Certificate of Correction ****

TITLE: DNA encoding CD40 ligand, a cytokine that binds CD40

Detailed Description Text (129):

These data indicate that the interaction of CD40 with its ligand is the principal molecular interaction responsible for T cell contact dependent induction of B cell growth and differentiation to both antigen-specific antibody production and polyclonal Ig secretion. As such, these data suggest that antagonists of this interaction, by soluble CD40, CD40/Fc fusion protein and possibly soluble CD40-L (monomeric), will significantly interfere with development of antibody responses. Therefore clinical situations where CD40, CD40/Fc fusion proteins and soluble CD40-L are suitable include allergy, lupus, rheumatoid arthritis, insulin dependent diabetes mellitus, and any other diseases where autoimmune antibody or antigen/antibody complexes are responsible for clinical pathology of the disease. Moreover, membrane-bound CD40-L or oligomeric soluble CD40-L will be useful to stimulate B cell proliferation and antibody production. As such, these forms of CD40-L are most useful for vaccine adjuvants and as a stimulating agent for mAb secretion from hybridoma cells.



Generate Collection

L3: Entry 28 of 29

File: USPT

Mar 2, 1999

DOCUMENT-IDENTIFIER: US 5876950 A

TITLE: Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy

Detailed Description Text (30):

The pharmaceutical compositions of the present invention find use in vivo to inhibit the CD40/gp39 interaction. Blocking this interaction limits both primary and secondary antibody responses to T-cell dependent antigens and antibody production specific for these antigens. Therefore, the monoclonal antibodies, antigen binding fragments, and recombinant binding proteins can be used to inhibit the activation of B cells, modulating or inhibiting autoimmune disease (i.e., psoriasis, rheumatoid arthritis, systemic lupus erythematosus, diabetes mellitus, etc.), allergic responses, organ rejection or graft-versus-host disease. The compositions can also be used for imaging tumors which express gp39, when labeled with a detectable marker. When conjugated with a therapeutic agent or as a fusion protein with a therapeutic agent, the monoclonal antibodies, antigen binding fragment or recombinant binding proteins, can also be used o target the therapeutic agent to tumor cells.

WEST[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)[Cases](#)**Search Results -**

Term	Documents
GP39	237
GP39S	0
CD40L	877
CD40LS	2
CD40	2267
CD40S	0
LIGAND	58523
LIGANDS	47955
5C8	98
5C8S	0
89-76	21
((GP39 OR CD40L OR CD40 ADJ LIGAND OR 5C8) SAME (ANTIBOD\$) AND ('89-76' OR '24-31')).USPT,PGPB.	23

There are more results than shown above. [Click here to view the entire set.](#)

Database:

US Patents Full-Text Database
US Pre-Grant Publication Full-Text Database
JPO Abstracts Database
EPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search:

L4

[Refine Search](#)[Recall Text](#)[Clear](#)**Search History**

DATE: Sunday, July 20, 2003 [Printable Copy](#) [Create Case](#)

[Generate Collection](#)[Print](#)

Term	Documents
GP39	237
GP39S	0
CD40L	877
CD40LS	2
CD40	2267
CD40S	0
LIGAND	58523
LIGANDS	47955
5C8	98
5C8S	0
89-76	21
((GP39 OR CD40L OR CD40 ADJ LIGAND OR 5C8) SAME (ANTIBOD\$) AND ('89-76' OR '24-31')).USPT,PGPB.	23

[There are more results than shown above. Click here to view the entire set.](#)

[Previous Page](#)[Next Page](#)

Term	Documents
GP39	237
GP39S	0
CD40L	877
CD40LS	2
CD40	2267
CD40S	0
LIGAND	58523
LIGANDS	47955
5C8	98
5C8S	0
89-76	21
((GP39 OR CD40L OR CD40 ADJ LIGAND OR 5C8) SAME (ANTIBOD\$) AND ('89-76' OR '24-31')).USPT,PGPB.	23

There are more results than shown above. Click here to view the entire set.

[Previous Page](#)

[Next Page](#)